MEDEA Biopharma
MEDEA Biopharma is a biopharmaceutical company founded in 2022, specializing in developing high-precision antimicrobials based on bacteriophages to target and eliminate harmful bacteria. Their mission is to revolutionize bacterial infection treatment and address antibiotic resistance by harnessing the full potential of phages for novel antimicrobial compounds. They validate bacterial targets, discover effective bacteriophages, and enable scalable tailored applications across various industries including animal health, aquaculture, and food protection.
Industries
Nr. of Employees
small (1-50)
MEDEA Biopharma
Services
Discovery workflows to identify bacteriophages active against validated bacterial targets and experimental validation of target susceptibility.
Development and adaptation of bacteriophage-based antimicrobial modalities for specific industry sectors such as animal health, aquaculture, and plant/food protection.
Discovery workflows to identify bacteriophages active against validated bacterial targets and experimental validation of target susceptibility.
Development and adaptation of bacteriophage-based antimicrobial modalities for specific industry sectors such as animal health, aquaculture, and plant/food protection.
Expertise Areas
- Phage-based antimicrobial lead discovery
- Bacterial target validation
- Bacteriophage isolation and screening
- Scaling bioprocesses for biological agents
Key Technologies
- Bacteriophage-based antimicrobials
- Phage isolation and screening
- Host-range profiling assays
- Bioprocess scale-up for biologics